Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
892.70
+1.38 (0.15%)
At close: Oct 25, 2024, 4:00 PM
891.81
-0.89 (-0.10%)
After-hours: Oct 25, 2024, 7:14 PM EDT
Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diabetes Revenue | 20.97B | 19.67B | 17.90B | 16.84B | 15.27B | 14.46B | 14.12B | 13.73B | ||||||||||||||||||||||
Diabetes Revenue Growth | 37.36% | 35.97% | 26.78% | 22.67% | 13.38% | 9.68% | 9.73% | 10.95% | ||||||||||||||||||||||
Oncology Revenue | 7.11B | 6.66B | 6.43B | 5.97B | 5.67B | 5.67B | 5.42B | 5.54B | ||||||||||||||||||||||
Oncology Revenue Growth | 25.46% | 17.51% | 18.46% | 7.85% | -0.92% | -1.31% | -7.25% | -4.13% | ||||||||||||||||||||||
Immunology Revenue | 3.85B | 3.80B | 3.63B | 3.51B | 3.37B | 3.34B | 3.37B | 3.51B | ||||||||||||||||||||||
Immunology Revenue Growth | 14.21% | 13.54% | 7.70% | 0.01% | -3.45% | -0.48% | 8.46% | 28.56% | ||||||||||||||||||||||
Neuroscience Revenue | 2.91B | 2.88B | 2.90B | 1.51B | 1.51B | 1.55B | 1.63B | 1.71B | ||||||||||||||||||||||
Neuroscience Revenue Growth | 92.66% | 86.18% | 77.83% | -11.84% | -17.58% | -18.56% | -14.25% | -11.16% | ||||||||||||||||||||||
Other Revenue | 1.09B | 1.12B | 1.22B | 1.69B | 1.87B | 3.52B | 4.70B | 4.59B | ||||||||||||||||||||||
Other Revenue Growth | -41.83% | -68.12% | -74.00% | -63.16% | -61.08% | -14.78% | 16.37% | 16.91% |
Revenue by Geography
Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
US Revenue | 23.05B | 21.79B | 19.99B | 19.05B | 17.45B | 18.19B | 18.71B | 18.27B | ||||||||||||||||||||||
US Revenue Growth | 32.07% | 19.80% | 6.88% | 4.23% | -3.28% | 8.20% | 15.24% | 18.63% | ||||||||||||||||||||||
Europe Revenue | 6.52B | 6.17B | 5.91B | 4.40B | 4.32B | 4.30B | 4.37B | 4.41B | ||||||||||||||||||||||
Europe Revenue Growth | 50.93% | 43.62% | 35.21% | -0.34% | -4.42% | -10.00% | -9.53% | -7.67% | ||||||||||||||||||||||
Rest of World Revenue | 3.17B | 2.95B | 3.02B | 2.88B | 2.77B | 2.85B | 2.79B | 2.85B | ||||||||||||||||||||||
Rest of World Revenue Growth | 14.14% | 3.30% | 8.23% | 0.86% | -2.49% | 5.55% | 7.88% | 14.80% | ||||||||||||||||||||||
China Revenue | 1.54B | 1.54B | 1.51B | 1.47B | 1.42B | 1.45B | 1.48B | 1.54B | ||||||||||||||||||||||
China Revenue Growth | 8.75% | 5.98% | 2.35% | -4.53% | -16.81% | -12.56% | -7.92% | 2.74% | ||||||||||||||||||||||
Japan Revenue | 1.65B | 1.67B | 1.63B | 1.73B | 1.72B | 1.75B | 1.89B | 1.99B | ||||||||||||||||||||||
Japan Revenue Growth | -4.35% | -4.28% | -13.70% | -13.48% | -21.81% | -26.18% | -24.40% | -22.13% |
Operating Expense Breakdown
Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Research and Development | 9.31B | 8.75B | 8.14B | 7.57B | 7.19B | 7.15B | 7.06B | 6.95B | |||||||||||||||||||||
Research and Development Growth | 29.52% | 22.26% | 15.30% | 8.84% | 2.35% | 3.62% | 5.99% | 8.98% | |||||||||||||||||||||
Marketing, Selling, and Administrative | 7.40B | 7.12B | 6.93B | 6.63B | 6.44B | 6.39B | 6.35B | 6.41B | |||||||||||||||||||||
Marketing, Selling, and Administrative Growth | 14.95% | 11.46% | 9.12% | 3.40% | 0.14% | -0.07% | -0.50% | 4.33% | |||||||||||||||||||||
Acquired In-Process Research and Development | 3.80B | 3.42B | 504.60M | 847.90M | 908.50M | 1.11B | 1.22B | 823.70M | |||||||||||||||||||||
Acquired In-Process Research and Development Growth | 318.25% | 208.95% | -58.68% | 2.94% | -6.35% | 23.08% | 69.37% | -10.48% | |||||||||||||||||||||
Impairment, Restructuring, and Other | 6.77M | - | - | - | 244.60M | 311.00M | - | - | |||||||||||||||||||||
Impairment, Restructuring, and Other Growth | -97.23% | - | - | - | -22.62% | - | - | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.